FDA Updates Master Protocol: What Developers Need to Know

The FDA released a revised draft guidance on June 22, 2026 offering updated recommendations on the design, analysis, and regulatory submission of clinical trials conducted under master protocols.1

The document is a revision of a December 2023 draft and reflects the FDA’s consideration of public comments received on that earlier version.1 The update adds expanded recommendations on basket trials and clarifies guidance on randomization, choice of control, and informed consent. The guidance addresses practical challenges that have historically complicated master protocol adoption for many drug developers.

Master protocols are structured to evaluate drugs across one or more diseases within a single overarching study framework.1 The three primary trial types covered are umbrella trials, which test multiple drugs against a single disease; basket trials, which evaluate a single drug across multiple diseases or disease subtypes; and platform trials, which allow drugs to enter and exit an ongoing evaluation structure over time. Each presents distinct design challenges that the guidance attempts to address with greater specificity than prior versions.

What Does the Guidance Say About Control Groups and Randomization?

One of the more technically significant sections concerns how control group data should be used in platform trials, where participants randomized to a control arm early in a long-running study may not have been eligible for drugs that entered the platform later.1 The guidance recommends that primary comparisons for any given drug use only concurrently eligible control participants, those who met drug-specific eligibility criteria and could have been randomized to that drug at the time of enrollment.

The agency acknowledged that using nonconcurrent control data can increase statistical precision, particularly in rare disease settings with constrained enrollment, but cautioned that temporal shifts in patient characteristics or standard of care can introduce bias that statistical adjustments may not fully correct.1 Sponsors who believe nonconcurrent controls are warranted are advised to discuss that rationale with the FDA early in planning.

On randomization, the guidance recommends allocating a greater proportion of participants to the shared control arm than to any individual drug arm in multi-drug trials.1 The mathematical basis for this, derived from minimizing the variance of each drug-versus-control comparison for a fixed total sample size, favors a control-to-drug ratio of the square root of the number of drugs being evaluated.

How Should Sponsors Approach Blinding and Regulatory Submissions?

Blinding presents another layer of complexity in master protocols, particularly when drugs being evaluated have different routes or schedules of administration.1 The guidance describes a range of approaches from complete blinding via multiple-dummy designs to partial blinding strategies in which participants know their assigned sub study but not whether they are receiving an active drug or placebo. The FDA recommends complete blinding where feasible, and open-label designs only in narrow circumstances where endpoints are objective and blinding would be highly impractical.

From a regulatory submission standpoint, each master protocol must be filed under a new Investigational New Drug Application.1 Sponsors are advised to request pre-submission meetings well in advance, given the layered coordination required among the master protocol sponsor, individual drug sponsors, and the FDA review divisions. The guidance includes detailed procedures for protocol amendments, cross-referencing between applications, and safety reporting obligations, all areas where multi-sponsor arrangements can generate compliance complexity.

What Other FDA's Moves Are Affecting the Broader Development Landscape?

FDA approved the first generic version of baloxavir marboxil tablets in June 2026, clearing a single-dose treatment option for acute uncomplicated influenza and post-exposure prophylaxis in patients five years and older.2 The approval, arrives ahead of the 2026–2027 flu season. Agency officials framed the decision around public health access, noting that influenza drives millions of illnesses annually in the United States. Generic drugs currently account for 9 out of 10 prescriptions filled domestically, and expanded generic availability is expected to introduce competitive pricing pressure on the existing market.

References

1. Master Protocols for Drug and Biological Product Development: Guidance for Industry. Draft Guidance. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research; Center for Biologics Evaluation and Research. June 2026.
2. FDA approves first single-dose generic treatment for influenza. Press Release. FDA. June 16, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-single-dose-generic-treatment-influenza